Cardiovascular problems can be associated with sleep apnea, and it's commonly assumed that treatment of sleep apnea could have cardiovascular benefits. But a ResMed ...
On May 15, 2015, Respironics, Inc., a Philips business, provided the following response to ResMed's Update on Phase IV SERVE-HF Study of Adaptive Servo-Ventilation (ASV) Therapy in Central Sleep Apnea ...
ResMed's shock result of its clinical trial, which put a group of patients at increased risk of dying and, in turn, closed the door on a new avenue of growth, has pushed the stock down 18 per cent.
- Largest-ever analysis of patients with treatment-emergent central sleep apnea shows switching from CPAP to ASV significantly improves compliance - Study highlights the need to consider therapeutic ...
Primary results from ResMed Inc.’s RMD CAT-HF trial showcased the significance of adaptive servo-ventilation (ASV) therapy in the treatment of heart failure (HF). Data were presented at the European ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results